ArticleLife (Basel, Switzerland)2025
Evaluation of Immunophenotypic Characteristics and Quantitative Differences of Telocytes Between Invasive Breast Cancer Subtypes.
Article in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Highly CD81-expressing stromal cells characterize a tumor-suppressive immune microenvironment in invasive breast cancer.Breast cancer research : BCR · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundBreast cancer is the most commonly diagnosed neoplasm in women and is classified into different molecular subtypes based on the expression characteristics of estrogen and progesterone receptors (ERs and PRs) and human epidermal growth factor 2 (HER2, ERBB2): Luminal A, Luminal B, HER2(+), and triple-negative breast cancer (TNBC). Telocytes, a new type of stromal cell, provide structural support for the preservation of organ integrity and play a crucial role in the tumor microenvironment. In this study, we evaluated telocyte counts and expression profiles among breast cancer subtypes.
methodsThe quantitative differences between telocytes in three subtypes of invasive breast cancer were assessed via immunohistochemistry, using vimentin, CD10, CD34, and c-Kit antibodies.
resultsVimentin(+), CD10(+), CD34(+), and c-Kit(+) telocyte counts were significantly higher in the Luminal and HER2(+) groups than in TNBC (
conclusionsOur results showed quantitative differences and marker expression profiles for telocytes between different breast cancer molecular subtypes. c-Kit(+) telocytes may contribute to the regulation of tumor size.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.